

Protalix BioTherapeutics, Inc.  
Form 8-K  
April 16, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): April 16, 2018 (April 15, 2018)**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-33357**

**65-0643773**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer  
Identification No.)

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices) (Zip Code)

20100

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. "

**Item 5.07 Submission of Matters to a Vote of Security Holders**

Protalix Biotherapeutics, Inc. (the “Company”) convened its 2018 Annual Meeting of Stockholders (the “Meeting”) at 1:00 p.m., Israel time, on April 15, 2018 at the offices of its Israeli counsel, Horn & Co., Law Offices, Amot Investments Tower, 2 Weizmann Street, 24th Floor, Tel Aviv 6423902, Israel. The Meeting was adjourned to May 13, 2018 at 1:00 p.m., Israel time, at the offices of its Israeli counsel, Horn & Co., Law Offices, Amot Investments Tower, 2 Weizmann Street, 24th Floor, Tel Aviv 6423902, Israel, to consider and vote upon the proposals described in the notice of meeting that was sent to each stockholder of record as of the close of business on February 26, 2018. The Meeting was adjourned to provide the Company with additional time to solicit proxies from its stockholders. The adjournment was approved by a vote of 79,256,545 shares of the Company’s common stock, with no shares voting against the adjournment or abstaining, and no broker non-votes, thus constituting approval by more than a majority of the shares of the Company’s common stock represented in person or by proxy at the Meeting and entitled to vote on the adjournment. The record date for the Meeting remains February 26, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 16, 2018 **PROTALIX  
BIOTHERAPEUTICS, INC.**

By: /s/ Yossi Maimon  
Name: Yossi Maimon

Title: Vice President and  
Chief Financial Officer